United States Patent and Trademark Office

Mithra’s NEXTSTELLIS® granted additional patent in the United States

Retrieved on: 
Tuesday, November 7, 2023
MITRA, ASX, Patent, Liver, United States Patent and Trademark Office, Tablet, 1836 U.S. Patent Office fire, Pregnancy, CET, Woman, Brussels Stock Exchange, Estetrol, MYX, Pharmaceutical industry, Birth control

Liege, Belgium, 07 November 2023 – 07:00 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, announces today that it has been granted an additional patent for NEXTSTELLIS® (3 mg drospirenone and 14.2 mg estetrol (E4) tablets) in the United States.

Key Points: 
  • Liege, Belgium, 07 November 2023 – 07:00 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, announces today that it has been granted an additional patent for NEXTSTELLIS® (3 mg drospirenone and 14.2 mg estetrol (E4) tablets) in the United States.
  • Granted by the United States Patent and Trademark Office, the new patent will provide NEXTSTELLIS® with oral-dosage-unit protection in the US market until 2036.
  • Mithra’s commercialization partner, Mayne Pharma Group Limited (ASX: MYX), holds the license and supply agreement for NEXTSTELLIS®/ESTELLE® in the United States since 2021.
  • David Horn Solomon, CEO of Mithra: “We are excited to have been granted this additional patent coverage for ESTELLE® under the trademark NEXTSTELLIS®, an oral contraceptive with a novel estrogen, in the United States.

EQS-News: Immunic Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis with Vidofludimus and Its Salts

Retrieved on: 
Tuesday, November 7, 2023
Patent, Food, Biotechnology, Multiple sclerosis, United States Patent and Trademark Office, MS, Lead, RMS, Patient, Calcium, Pharmaceutical industry, Short course immune induction therapy

The claims are expected to provide protection into 2041, unless extended further.

Key Points: 
  • The claims are expected to provide protection into 2041, unless extended further.
  • “Importantly, this patent for the dose strength in RMS patients covers all salt and free acid forms of vidofludimus calcium.
  • In the United States, these patents provide protection into 2041, unless extended further.
  • On top of the patent exclusivity, vidofludimus calcium, as a new chemical entity, should also benefit from regulatory data protection.

ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing

Retrieved on: 
Monday, November 6, 2023
Adenosine deaminase, ADAR, Patent, RNA, Adenosine, Intellectual property, Oligonucleotide, ProQR, RNA editing, European Patent Office, United States Patent and Trademark Office, Inosine, Therapy, European Patent Convention, IP, General counsel, Japan Patent Office, 3D printing, Vaccine

“The new patent that the USPTO granted to ProQR further expands the protection of RNA editing using oligonucleotides to recruit endogenous ADAR.

Key Points: 
  • “The new patent that the USPTO granted to ProQR further expands the protection of RNA editing using oligonucleotides to recruit endogenous ADAR.
  • Our leading intellectual property portfolio protects our Axiomer® ADAR-mediated RNA editing platform technology and more fundamentally the use of an oligonucleotide to recruit endogenous deaminating enzymes in the cell,” said René Beukema, Chief Corporate Development Officer and General Counsel.
  • Since then, ProQR has filed multiple additional patent applications on further improvements to form a leading patent estate that makes RNA editing with oligonucleotides that recruit endogenous ADAR proprietary to ProQR.
  • Beyond this, ProQR has several unpublished patent applications and continuously invests in expanding its IP estate around ADAR-mediated RNA editing.

Arcutis Announces Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Friday, November 3, 2023
Janus, FDA, Psoriasis, Research, JAK1, Patent, ESG, GTN, SG, Human, Acquisition, Environmental, social, and corporate governance, Biophysical environment, United States Patent and Trademark Office, Inflammation, Hair, R, Senior, Growth, Prescription, Marketing, Shanda, Webcast, SLR, New Drug Application, Scalp, PDE4, NDA, Atopic dermatitis, Patient, Dermatitis, Acceleration, Alopecia areata, Video game, Pharmaceutical industry, Security (finance), Fine chemical, Vaccine, Cosmetics

The Company anticipates further GTN improvement in the fourth quarter of 2023.

Key Points: 
  • The Company anticipates further GTN improvement in the fourth quarter of 2023.
  • In October 2023, Arcutis received FDA approval for ZORYVE for an expanded indication for the treatment of plaque psoriasis in children down to 6 years of age.
  • In September 2022, Arcutis announced positive topline results from the ARRECTOR Pivotal Phase 3 trial for the treatment of scalp and body psoriasis.
  • Arcutis management will host a conference call and webcast today at 8:30am ET to discuss the financial results for the quarter and provide a business update.

Catalyst Pharmaceuticals Receives Two New U.S. Patent Allowances For FIRDAPSE®

Retrieved on: 
Thursday, November 2, 2023
CORAL, Fasting, Patent, Rare, United States Patent and Trademark Office, Orange Book, Catalyst Pharmaceuticals, Amifampridine, Approved Drug Products with Therapeutic Equivalence Evaluations, Lambert–Eaton myasthenic syndrome, Tablet, Patient, NAT2, Pharmaceutical industry, Catalysis

FIRDAPSE is the only approved treatment available in the U.S. for Lambert-Eaton myasthenic syndrome.

Key Points: 
  • FIRDAPSE is the only approved treatment available in the U.S. for Lambert-Eaton myasthenic syndrome.
  • "We are very pleased to receive these patent notifications from the USPTO.
  • "These patent allowances strengthen our cumulative understanding of the uniqueness of FIRDAPSE and bolster its strong intellectual property estate offering enhanced patent protection," stated Dr. Steven Miller, Chief Operating Officer and Chief Scientific Officer of Catalyst.
  • Preparations are already in motion to include these additional FIRDAPSE patents in the FDA Orange Book post-grant, bringing the total listed patent count to eight."

EXPANDING POSSIBILITIES: CANON ANNOUNCES FIRMWARE UPDATES FOR CINEMA EOS, CAMCORDER AND PTZ CAMERAS, GRANTING CANON CUSTOMERS BROADER OPTIONS AND MORE CONTROL

Retrieved on: 
Thursday, November 2, 2023
EOS, CR, United States Patent and Trademark Office, XF, RF, RCCA, PTZ, Canon Cinema EOS, SRT, Wi-Fi, IPhone, Shutter, Canon Inc., Canon EOS C300 Mark II, Zoom, Lens, Color balance, Iris, R5, ISO, Patent, Camera, Typesetting, Citrus, Telescopic sight, Consumer electronics, Television, Video game, Canon

Additionally, Canon announced the new Canon Multi-Camera Control App (the “app”)1.

Key Points: 
  • Additionally, Canon announced the new Canon Multi-Camera Control App (the “app”)1.
  • All firmware updates and the app will be available to customers for free download in early December 2023*.
  • Highlights for each of the Canon Cinema EOS products:
    Supports camera control from the new RC-IP1000 Remote Camera Controller.
  • Enhancements to the vector scope will now enable display of the vector color and color-space on screen.

Applied UV Inc. Secures New Patent Approval From the USPTO for Interchangeable Drain Disinfecting Device Undergoing Validation at Mt Sinai Hospital

Retrieved on: 
Thursday, November 2, 2023
Puro, Building, Patent, National Institutes of Health Office of Science Policy, Hospital, Federation, Infection, United States Patent and Trademark Office, Disinfectant, U.S. federal government response to the COVID-19 pandemic, Fighter, The Fighter, Purdue University, Partnership, Food security, Health, Safety, Johnson Controls, Hygiene, Food storage, Sewage treatment, Plumbing, 3D printing, Heating, ventilation, and air conditioning, Medical device, UV, HVAC

New Patent Approval - Interchangeable Drain Disinfecting Device:

Key Points: 
  • New Patent Approval - Interchangeable Drain Disinfecting Device:
    The Company’s patent for this innovative device optimizes UV source irradiation to effectively disinfect drain systems, contributing to enhanced hygiene and safety.
  • This strategic development aligns with Applied UV Inc.'s commitment to providing cutting-edge solutions for healthier living and working environments.
  • Current Testing at Mt Sinai University Hospital, NYC:
    Applied UV’s Interchangeable Drain Disinfecting Device is currently undergoing rigorous testing at the esteemed Mt Sinai Hospital System in New York City.
  • For more information about these recent patent approvals and Applied UV Inc.'s innovative solutions, please visit our website and explore the press release section at https://www.applieduvinc.com .

Super League Granted New Patent Allowance Related to AI Optimization of Live Streaming Content; Company Remains at the Forefront of Technical Innovation

Retrieved on: 
Wednesday, November 1, 2023
Minecraft, Patent, Super League, Intellectual property, United States Patent and Trademark Office, Charli XCX, MTV, Video, Charli, Video game, Television

Specifically, the company’s newest patent pertains to the production and intelligent prioritization of simultaneous perspectives within virtual environments, especially video games, for the purpose of creating compelling experiences and content.

Key Points: 
  • Specifically, the company’s newest patent pertains to the production and intelligent prioritization of simultaneous perspectives within virtual environments, especially video games, for the purpose of creating compelling experiences and content.
  • “Producing compelling content related to virtual experiences remains a core competency of Super League, and this new patent allows us to further distinguish ourselves by increasing the quality of results while also greatly improving the efficiency of production.
  • In addition, for the last three years, Super League has produced monthly world-wide esports events for Top Golf's live WGT Golf series.
  • This patent application grows Super League’s already substantial patent portfolio, which encompasses a multitude of innovations including those related to AI, custom visualization, audience targeting and more.

Applied UV Inc. Granted Significant New Patents by USPTO and Enters Into Strategic Partnership With Canon Virginia, Inc.

Retrieved on: 
Monday, October 30, 2023
Puro, Patent, Health, PCO, Federation, United States Patent and Trademark Office, U.S. federal government response to the COVID-19 pandemic, Fighter, Ushio, Purdue University, Canon Inc., Partnership, HVAC, Safety, Sewage treatment, 3D printing, Pharmaceutical industry

NEW YORK, NY, Oct. 30, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Applied UV Inc. (NASDAQ: AUVI), a pioneer in UV disinfection technology, is elated to announce today that the United States Patent and Trademark Office (USPTO) issued a patent US 2023/0059472 A1 for the Company’s Airo™ Vortex, encompassing advanced disinfection capabilities and Photocatalytic Oxidation (PCO). Concurrently, the Company also received publication notice on its Fighter Flex™ LED

Key Points: 
  • These milestones underscore a significant stride in Applied UV Inc.’s capabilities and focus on advancing innovation in the disinfection domain, with an aim to foster safer and healthier environments for all.
  • At the 2023 Global Produce & Floral Show held last week, Applied UV Inc. and strategic partner, Canon Virginia, Inc. (a unit of Canon USA) showcased its next-generation Airocide™ technology, which incorporates its patented Airo vortex design.
  • This initiative is further bolstered by an ongoing partnership for additional testing with Johnson Controls and Ushio at Purdue University.
  • This extensive realm of testing highlights the potential and efficacy of Applied UV Inc.’s technologies in addressing diverse community requisites.

MannKind Expands Patent Portfolio With New Clofazimine Formulation Patent

Retrieved on: 
Monday, October 30, 2023
FDA, Prevalence, Infection, United States Patent and Trademark Office, Cough, Environment, QIDP, Lung, Quality of life, MannKind Corporation, Disease, Risk, Doctor of Pharmacy, Bacteria, Urinary tract infection, Clofazimine, Woman, Patient, NTM, Fatigue, Pharmaceutical industry, Patent

11,793,808) issued by the United States Patent and Trademark Office covering clofazimine inhalation suspension (MNKD-101), which is under development for the potential treatment of nontuberculous mycobacterial (NTM) lung disease.

Key Points: 
  • 11,793,808) issued by the United States Patent and Trademark Office covering clofazimine inhalation suspension (MNKD-101), which is under development for the potential treatment of nontuberculous mycobacterial (NTM) lung disease.
  • The patent will expire on June 8, 2039.
  • “We believe this patent represents important protection for our lead pipeline asset, MNKD-101, that could potentially improve therapy for a disease that is increasingly on the rise globally,” said Michael Castagna, PharmD, Chief Executive Officer for MannKind Corporation.
  • “Patients living with NTM typically rely on a series of drug treatments that often may be associated with severe side effects.